-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A new study from the Joan .
The expression of TYMP, a gene that plays an important role in platelet activation, thrombosis and inflammation, was significantly elevated in COVID-19 patient.
"This study demonstrates for the first time that the SARS-CoV-2 spike protein is sufficient to enhance the expression of TYMP and the activation of NF-kB," said Wei Li, P.
Li and his team presented the research last month at the International Society of Thrombosis and Hemostasis (ISTH) 2022 Congress in London, Englan.
Using the human ACE2 gene that mediates SARS-CoV-2 invasion into host cells, transgenic mice, and a mouse thrombosis model, the researchers observed for the first time that intraperitoneal injection of the SARS-CoV-2 spike protein in mice enhanced thrombosis, which could be inhibited by tipiracil, a selective TYMP inhibitor and FDA-approved dru.
In addition to Li, Renat Roytenberg, Autumn DeHart, D.
The researchers are looking for partners and collecting patient samples to develop TYMP as a biomarker for diagnosing the severity of COVID-19. Additional ongoing studies are elucidating the mechanisms that mediate the increased expression of TYMP by the SARS-CoV-2 spike protein, and the potential impact of TYMP in prolonged COVID-19.
